STAFFORDSHIRE pharmaceuticals group Dechra said today it had made a “solid start” to its financial year and had enjoyed strong growth in its US operations.
In a trading update for the period since July 1, 2011, the Stoke-based veterinary products firm says it has started the financial year in line with management expectations with revenue in Q1 7.7% ahead of the same period last year.
Its European pharmaceuticals division grew revenues in the first quarter by 10.5% while branded pharmaceutical product revenues increased by 10.3% at constant currency year-on-year.
Diets revenue, however, were “flat” due to phasing of export orders while gross margin stabilised in the period, it said.
